EN - NL Type 1 diabetes mellitus - type 1 diabetes mellitus Hypoglycaemia - hypoglykemie Glucagon - glucagon
Conditions
Interventions
The 16 type 1 patients will be randomised to one of two treatment sequences: DPP-4 inhibitor followed by placebo or placebo followed by a DPP-4 inhibitor. Each treatment period lasts 6 weeks, so all p
Sponsors
Academic Medical Center, Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male; 2. Age 18-40 years; 3. Type 1 Diabetes Mellitus 5-20 years duration; 4. C-peptide negative; 5. Willing and able to give written informed consent.
Exclusion criteria
Exclusion criteria: 1. Impaired awareness of hypoglycaemia; 2. BMI > 27 kg/m2; 3. Evidence of severe diabetes complications (autonomic neuropathy, macroalbuminuria, proliferative retinopathy); 4. Acute illness within 3 months before the study; 5. Significant renal impairment (creatinine clearance <50ml/min); 6. Use of beta-adrenoreceptor blockers; 7. Cardiac history (previous arrhythmia); 8. History of epilepsy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glucagon response to insulin induced hypoglycaemia measured as AUC (area under the curve). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Other counterregulatory hormone responses to insulin induced hypoglycaemia measured as AUC; 2. Symptomatic hormone responses to insulin induced hypoglycaemia. | — |
Contacts
Public ContactF. Holleman
Postbus 22660
Outcome results
None listed